
    
      Successive cohorts of three or more patients were treated at escalating doses until a maximum
      tolerated dose/recommended phase 1 dose was identified. Once the maximum tolerated dose was
      identified, an Expansion Cohort was enrolled at that dose to further characterize safety and
      to explore pharmacodynamic endpoints.
    
  